Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: siRNA therapeutics - OliX Pharmaceuticals

Drug Profile

Research programme: siRNA therapeutics - OliX Pharmaceuticals

Alternative Names: asiRNA therapeutics - OliX Pharmaceuticals; cp-asiRNA therapeutics - OliX Pharmaceuticals; OLX 103; OLX 201; OLX 301; OLX 401; OLX 701

Latest Information Update: 22 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioMolecular Therapeutics
  • Developer OliX Pharmaceuticals; University of Virginia School of Medicine
  • Class Antifibrotics; Eye disorder therapies; Skin disorder therapies; Small interfering RNA
  • Mechanism of Action Connective tissue growth factor inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Atopic dermatitis; Hepatic fibrosis; Idiopathic pulmonary fibrosis; Neuropathic pain
  • Discontinued Cancer; Herpes simplex virus infections

Most Recent Events

  • 22 Jan 2018 Olix Pharmaceuticals has patent pending for cp-asiRNA technology in USA, Europe, Japan and China (Olix Pharmaceuticals website, January 2018)
  • 22 Jan 2018 Olix Pharmaceuticals has patent protection for cp-asiRNA technology in South Korea (Olix Pharmaceuticals website, January 2018)
  • 22 Jan 2018 Discontinued - Preclinical for Cancer in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top